Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Oct 21:12:781872.
doi: 10.3389/fimmu.2021.781872. eCollection 2021.

Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer

Said Dermime  1   2   3 , Maysaloun Merhi  1   2 , Taha Merghoub  4   5   6   7
Affiliations
Editorial

Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer

Said Dermime et al. Front Immunol. .
No abstract available

Keywords: dynamic biomarkers; immune checkpoint inhibitors (ICI); irAEs; programmed cell death ligand 1 (PD-L1); programmed cell death protein 1 (PD1).

PubMed Disclaimer

Conflict of interest statement

TM has acted as a consultant for Immunogenesis, Immunos Therapeutics and Pfizer, has received research support from Adaptive Biotechnologies, Aprea, Bristol Myers Squibb, Infinity Pharmaceuticals, Kyn Therapeutics, Leap Therapeutics, Peregrine Pharmaceuticals and Surface Oncology, is listed as a co-inventor on patents relating to the use of oncolytic viral therapy, alphavirus-based vaccines, antibodies targeting CD40, GITR, OX40, PD-1 and CTLA-4 and neo-antigen modelling, and is a cofounder of and holds an equity in IMVAQ Therapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer

Similar articles

See all similar articles

Cited by

References

    1. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. . Pembrolizumab Versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 372(26):2521–32. doi: 10.1056/NEJMoa1503093 - DOI - PubMed
    1. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. . Overall Survival With Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med (2017) 377(14):1345–56. doi: 10.1056/NEJMoa1709684 - DOI - PMC - PubMed
    1. Relecom A, Merhi M, Inchakalody V, Uddin S, Rinchai D, Bedognetti D, et al. . Emerging Dynamics Pathways of Response and Resistance to PD-1 and CTLA-4 Blockade: Tackling Uncertainty by Confronting Complexity. J Exp Clin Cancer Res (2021) 40(1):74. doi: 10.1186/s13046-021-01872-3 - DOI - PMC - PubMed
    1. Merhi M, Raza A, Inchakalody VP, Siveen KS, Kumar D, Sahir F, et al. . Persistent Anti-NY-ESO-1-Specific T Cells and Expression of Differential Biomarkers in a Patient With Metastatic Gastric Cancer Benefiting From Combined Radioimmunotherapy Treatment: A Case Report. J Immunother Cancer (2020) 8(2). doi: 10.1136/jitc-2020-001278 - DOI - PMC - PubMed
    1. Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, et al. . Integrated NY-ESO-1 Antibody and CD8+ T-Cell Responses Correlate With Clinical Benefit in Advanced Melanoma Patients Treated With Ipilimumab. Proc Natl Acad Sci USA (2011) 108(40):16723–8. doi: 10.1073/pnas.1110814108 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances